Greg A Gerhardt
Overview
Explore the profile of Greg A Gerhardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
165
Citations
3503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quintero J, Chau M, Slevin J, Koehl L, Gurwell J, Wallace E, et al.
J Parkinsons Dis
. 2025 Feb;
:1877718X241312409.
PMID: 40007169
Background: Motor dysfunction in Parkinson's disease (PD) is characterized by a loss of functioning neurons in the substantia nigra. Two options exist when encountering damaged neurons: replace or support. We...
2.
Aparicio G, Quintero J, Plum L, Deng L, Wanczyk K, Henry M, et al.
J Peripher Nerv Syst
. 2024 Jul;
29(3):294-314.
PMID: 38973168
Background And Aims: The goal of this study was to define basic constituents of the adult peripheral nervous system (PNS) using intact human nerve tissues. Methods: We combined fluorescent and...
3.
Kurepa J, Bruce K, Gerhardt G, Smalle J
Appl Biosci (Basel)
. 2024 Jun;
3(2):233-249.
PMID: 38835931
Synucleinopathies, typified by Parkinson's disease (PD), entail the accumulation of -synuclein (Syn) aggregates in nerve cells. Various Syn mutants, including the Syn A53T variant linked to early-onset PD, increase the...
4.
Colvett I, Gilmore A, Guzman S, Ledreux A, Quintero J, Ginjupally D, et al.
J Clin Med
. 2023 Oct;
12(19).
PMID: 37834764
Parkinson's disease (PD) is a severe neurological disease for which there is no effective treatment or cure, and therefore it remains an unmet need in medicine. We present data from...
5.
Fernandes E, Ledo A, Gerhardt G, Barbosa R
Talanta
. 2023 Oct;
268(Pt 1):125302.
PMID: 37826935
Epilepsy is a prevalent neurological disorder with a complex pathogenesis and unpredictable nature, presenting limited treatment options in >30 % of affected individuals. Neurometabolic abnormalities have been observed in epilepsy...
6.
Hixson J, Quintero J, Guiliani A, Yamasaki T, Gerhardt G, Slevin J, et al.
J Parkinsons Dis
. 2023 Mar;
13(3):421-426.
PMID: 36938741
We sought to design a data visualization platform to represent the Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) item scores in an easy-to-use display without modification of the...
7.
Kalimon O, Vekaria H, Gerhardt G, Sullivan P
Exp Neurol
. 2023 Feb;
363:114356.
PMID: 36841465
Monoamine oxidase (MAO) is an enzyme located on the outer mitochondrial membrane that metabolizes amine substrates like serotonin, norepinephrine and dopamine. MAO inhibitors (MAOIs) are frequently utilized to treat disorders...
8.
Chau M, Quintero J, Blalock E, Byrum S, Mackintosh S, Samaan C, et al.
PLoS One
. 2022 Nov;
17(11):e0260998.
PMID: 36417411
Regeneration after severe peripheral nerve injury is often poor. Knowledge of human nerve regeneration and the growth microenvironment is greatly lacking. We aimed to identify the regenerative proteins in human...
9.
Chau M, Quintero J, Monje P, Voss S, Welleford A, Gerhardt G, et al.
Cell Transplant
. 2022 Sep;
31:9636897221123515.
PMID: 36169034
One promising strategy in cell therapies for Parkinson's disease (PD) is to harness a patient's own cells to provide neuroprotection in areas of the brain affected by neurodegeneration. No treatment...
10.
Quintero J, Slevin J, Gurwell J, McLouth C, El Khouli R, Chau M, et al.
BMJ Neurol Open
. 2022 Aug;
4(2):e000301.
PMID: 35949912
Objective: To evaluate the interim feasibility, safety and clinical measures data of direct delivery of regenerating peripheral nerve tissue (PNT) to the substantia nigra (SN) in participants with Parkinson's disease...